Jazz Pharmaceuticals (JAZZ) CEO Gala Renee D Sells 3,967 Shares

What Happened Gala Renee D, President & CEO of Jazz Pharmaceuticals, disposed of a total of 3,967 JAZZ shares on September 8, 2026, generating roughly $971,535. Specifically, 1,967 shares were withheld to satisfy tax obligations related to vested restricted stock units (1,967 × $246.81 = $485,475), and 2,000 shares were sold in an open‑market transaction (2,000 × $243.03 = $486,060). These are sales/withholdings (not purchases), which are often routine actions tied to compensation and preplanned selling programs rather than new bullish purchases.

Key Details

• Transaction dates: September 8, 2026.
• Prices and amounts:
  • Tax withholding: 1,967 shares at $246.81 each = $485,475 (code F).
  • Open‑market sale: 2,000 shares at $243.03 each = $486,060 (code S).
• Total proceeds/consideration: ~ $971,535.
• Shares owned after transaction: Not specified in the filing.
• Footnotes:
  • F1: Shares were withheld to satisfy tax obligations from vesting of previously granted restricted stock units.
  • F2: The 2,000‑share sale was made under a Rule 10b5‑1 plan adopted June 4, 2026; the sale occurred automatically and was not a discretionary trade by the CEO.
• Filing: Form 4 filed Sept 10, 2026 (no late filing indicated in the report).

Context

• The 1,967‑share action is a tax withholding tied to RSU vesting (common and routine). The 2,000‑share sale was executed under a preplanned 10b5‑1 program, which typically means the sale was automatic per the plan terms rather than a discretionary decision by the insider. Sales and tax withholdings are common and do not necessarily signal a change in the insider’s view of the company; retail investors often place greater emphasis on open‑market purchases when assessing insider conviction.